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Gastric cancer is considered a chemosensitive disease and second
generation combination chemotherapy regimens have produced
high response rates and impressive survival times (Hill and
Cunningham, 1998). Unfortunately, about half of the patients
treated with chemotherapy is unresponsive, and less than half of
the patients with locally advanced disease is amenable of surgical
resection after neoadjuvant chemotherapy. For these reasons, new
and hopefully more effective drugs, or innovative treatment strate-
gies are needed. 
Docetaxel is a semisynthetic taxoid with cytotoxic activity
against a broad spectrum of human solid tumors (Cortes and
Pazdur, 1995). Docetaxel has been tested in advanced gastric
cancer and it showed promising single-agent activity with 20% to
24% response rates in treated and chemotherapy-naive patients
(Sulkes et al, 1994; Furue and Taguchi, 1998; Mavroudis et al,
1999; Vanhofer et al, 1999). A logical step of investigation
consisted in the development of multi-drug schedules including
docetaxel and other known active drugs. In early phase II studies,
combinations of docetaxel with cisplatin, fluorouracil or epi-
doxorubicin showed promising results, but neutropenia and non-
haematologic toxicity were often significant (Ajani et al, 1999;
Andrè et al, 1999; Roth et al, 2000). 
Ongoing studies are exploring new schedules of docetaxel-
based combination chemotherapy to ameliorate the efficacy/toxi-
city ratio. Sequential schedules may maximize the dose-intensity
of each single agent and avoid the overlapping toxicity caused by
the concomitant administration of active drugs. Safety and effic-
acy of sequential chemotherapy with docetaxel has been tested in
breast cancer with favourable results (Antoine et al, 1998), and
this chemotherapeutic strategy deserves investigation in other
tumors with documented activity of docetaxel (Pronk et al, 1995). 
In advanced gastric cancer, we investigated safety and activity
of sequential chemotherapy with docetaxel after the intensive
weekly PELF regimen (Cascinu et al, 1997, 1998). 
MATERIALS AND METHODS 
Patient selection 
Chemotherapy-naive patients with pathologically confirmed,
relapsed or metastatic gastric cancer were considered eligible for
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42.5% to 72.5%). The PELF regimen did not cause any grade IV toxicity, the most frequent grade III acute side-effects were
thrombocytopenia and vomiting which occurred in the 10% of 320 PELF cycles. Docetaxel caused grade III–IV neutropenia and
thrombocytopenia in the 10% and the 19% of cycles respectively. Fatigue was a frequent side-effect during both PELF and docetaxel
chemotherapy. The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity.
This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy. © 2001 Cancer Research Campaign
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the study. Other eligibility criteria were: Eastern Cooperative
Oncology Group (ECOG) performance status 0, 1, or 2; age equal
or less than 75 years; normal liver, renal, and bone marrow func-
tions. The protocol was approved by each local institutional
review board and all patients gave written informed consent. 
Treatment plan 
PELF chemotherapy consisted of a 1 day per week administration
of cisplatin 40 mg/m2, fluorouracil 500 mg/m2, epi-doxorubicin
35 mg/m2, 6S-stereoisomer of leucovorin 250 mg/m2 and
glutathione 1.5 g/m2. All drugs were given intravenously and on
the other days filgrastim was administered by subcutanous injec-
tion at a dose of 5 mg kg–1 (Cascinu et al, 1997). After 8 weekly
cycles patients were re-evaluated and those with partial response
or stable disease received docetaxel 100 mg/m2 via a 1-hour intra-
venous infusion every 3 weeks. After 3 cycles with docetaxel
patients were re-evaluated for response to the sequential treatment.
All patients received emesis prophylaxis with 5-HT3 inhibitors
and hyperhydration during each course of PELF chemotherapy.
Patients who received docetaxel were treated with dexamethasone
8 mg p.o. administered 12 and 6 hours before drug infusion and
8 mg twice daily for an additional 4 days. 
Full doses of the anticancer drugs were given if the neutrophil
count was equal or >1.5 ´ 109 l–1 and the platelet count equal or
>100 ´ 109 l–1; dose reductions were not recommended and values
less than these necessitated a 7-day treatment delay. Patients
treated with docetaxel did not receive prophylactic haematopoietic
growth factors. However, filgrastim was employed in patients with
grade III neutropenia lasting more than one week or grade IV
neutropenia, so that treatment at the 100 mg/m2 dose level could
be maintained. 
Evaluation procedures 
Pretreatment evaluation consisted of baseline studies including:
medical history, physical examination, blood chemistries, urino-
analysis and ECG. Also, chest X-rays, abdominal computed
tomography or magnetic resonance, bone scan and any other test
to identify the extent of disease was performed. These studies were
repeated after 8 weekly administration of PELF chemotherapy,
after 3 cycles of docetaxel and every 3 months thereafter.
Responses to the sequential program were not confirmed by an
early repeat estimation. 
All patients had physical examination and biochemical profile
before each administration of chemotherapy. Response and toxi-
city were evaluated and graduated according to the standard World
Health Organization (WHO) criteria (Miller et al, 1981). Patients
treated with docetaxel with no fluid retention were considered
grade 0; asymptomatic weight gain, grade 1; mild peripheral
oedema that did not require diuretics, grade 2; symptomatic,
moderate edema tha required diuretics, grade 3; edema/fluid
retention that necessitated docetaxel withdrawal, grade 4. 
Statistical plan 
The optimal two-stage design was adopted for this phase II trial
(Simon, 1989). The minimum target activity level was a 20% gain
in objective responses attained by docetaxel after the PELF
regimen. Early discontinuation of the study was planned in the
case of no response in the first 12 assessable patients treated with
docetaxel (a and  b error probabilities 0.010 and 0.010).
Alternatively, a planned sample size of approximately 30 patients
was chosen to better estimate efficacy; 35% maximum width of
the 95% confidence interval (CI) for the overall response rate.
Time to disease progression was measured from date of registra-
tion to the date of progressive disease. Overall survival was
measured form the time of registration to the date of death
resulting from any cause. 
RESULTS 
Between October 1998 and November 1999 40 patients entered
this study and they are fully evaluable for response and toxicity.
Their characteristics are reported in Table 1. 
The toxicity profile of the PELF regimen was acceptable and it
was similar to that of previous studies. None of the 40 patients
suffered from grade IV toxicity and 12 patients (35.3%) experi-
enced acute grade III adverse events. The major grade III toxicities
were thrombocytopenia and vomiting which occurred in the 10%
of 320 PELF cycles (Table 2). The most frequent chronic adverse
events attributable to the PELF regimen (Table 3) were grade III
alopecia in the 88% of the patients and grade II asthenia in the
25% of the patients. Transient grade II peripheral neuropathy
occurred in 2 patients. All the 40 patients received eight cycles,
but due to neutropenia and/or thrombocytopenia, the 30% of 320
PELF administrations were delayed a week. After the PELF
regimen, 3 patients achieved complete response, 13 patients
showed partial response, 21 patients had stable disease and 3
patients progressed (40% response rate; 95% CI 25% to 55%). 
According to the treatment protocol 34 patients started
docetaxel and all of them completed 3 cycles of chemotherapy.
Acute adverse events in 102 cycles are listed in Table 4; grade
III–IV neutropenia and thrombocytopenia occurred in the 10% and
the 19% of cycles, respectively. None of the patients experienced
neutropenic fever or sepsis, but 10 patients with grade III/IV
neutropenia were treated with prophylactic filgrastim to maintain
the planned dose of chemotherapy. Due to neutropenia and/or
thrombocytopenia, docetaxel was delayed a week in the 45% of
102 cycles. One patient with grade III dermatitis had 50% dose
reduction in the last administration of docetaxel. Asthenia was the
most frequent chronic adverse events (Table 5) and it resulted
grade I/II in 18 patients and grade III in 2 patients. None of the
Table 1 Characteristics of the 40 patients enrolled in the study 
Number of patients 40 
Sex ratio M/F 23/17 
Median age (range) 57 y (38–69) 










Lymph nodes + abdominal mass 13 
Liver + lymph nodes 5 
Local relapse 5 
Lung + liver 2 
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Table 2 Acute adverse events associated with the PELF regimen in 320 cycles 
WHO Grade 
Toxicity 0 1 2 3 
No of cycles (%) No of cycles (%) No of cycles (%) No of cycles (%) 
Neutropenia 186 (58) 76 (24) 38 (12) 20 (6) 
Thrombocytopenia 177 (55) 50 (15) 63 (20) 30 (10) 
Anaemia 189 (59) 70 (21) 40 (12) 21 (8) 
Nausea/vomiting 140 (43) 99 (31) 50 (16) 31 (10) 
Diarrhoea 200 (62) 79 (24) 41 (14) 0 
Mucositis 274 (85) 33 (11) 13 (4) 0 
None of the patients treated with the PELF regimen experienced grade 4 side-effects. 
Table 3 Chronic adverse events associated with the PELF regimen in 40 enrolled patients 
WHO Grade 
Toxicity 0 1 2 3 
No of pts (%) No of pts (%) No of pts (%) No of pts (%) 
Asthenia 22 (55) 8 (20) 10 (25) 0 
Peripheral neurotoxicity 32 (80) 6 (15) 2 (5) 0 
Nail toxicity 33 (82) 4 (10) 3 (8) 0 
Constipation 20 (50) 20 (50) 0 0 
Alopecia 0 0 5 (12) 35 (88) 
None of the patients treated with the PELF regimen experienced grade 4 side-effects. 
Table 4 Acute adverse events attributable to docetaxel in 102 cycles
WHO Grade 
012 3 4  
Toxicity No of cycles (%) No of cycles (%) No of cycles (%) No of cycles (%) No of cycles (%) 
Neutropenia 20 (19) 37 (36) 35 (35) 9 (9) 1 (1) 
Thrombocytopenia 18 (17) 42 (41) 23 (23) 19 (19) 0 
Anaemia 48 (47) 40 (39) 14 (14) 0 0 
Nausea/vomiting 12 (12) 44 (43) 31 (30) 15 (15) 0 
Diarrhoea 68 (67) 22 (21) 12 (12) 0 0 
Mucositis 87 (85) 12 (12) 3 (3) 0 0 
Skin toxicity 66 (65) 24 (23) 11 (11) 1 (1) 0 
Myalgias 77 (75) 13 (13) 2 (2) 0 0 
Dacryorrhoea 68 (67) 34 (33) 0 0 0 
Table 5 Chronic adverse events attributable to docetaxel in 34 patients 
WHO Grade 
012 3  
Toxicity No of pts (%) No of pts (%) No of pts (%) No of pts (%) 
Asthenia 14 (42) 8 (23) 10 (29) 2 (6) 
Peripheral neurotoxicity 28 (82) 2 (6) 4 (12) 0 
Fluid retention 29 (85) 0 5 (15) 0 
Constipation 30 (88) 4 (12) 0 0 
Nail toxicity 68 (67) 22 (21) 4 (12) 0 
Alopecia 0 0 2 (6) 32 (94) 
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patients experienced hypersensitivity reactions but moderate fluid
retention syndrome was observed in 5 patients. 
None of the 34 patients progressed during docetaxel
chemotherapy and 9 of them (26.5%) gained a major response; 7
patients with stable disease improved to partial response and 
2 patients with partial response achieved complete response.
Excluding from the overall response rate the two patients who
improved partial response to complete response, the PELF-
docetaxel regimen produced unconfirmed objective responses in
23 out of 40 patients (57.5% response rate with 95% CI, 42.5% to
72.5%). Time to disease progression and median survival time
resulted 7 months and 12.6 months, respectively. 
DISCUSSION 
Recent phase II studies have established the role of docetaxel in
first-line and second-line treatment of advanced gastric cancer
(Sulkes et al, 1994; Furue and Taguchi, 1998; Mavroudis et al,
1999). As a consequence, the hope for more potent regimens
prompted several investigators to evaluate docetaxel in multi-
drug regimens. Early investigations of polychemotherapy with
docetaxel, cisplatin and fluorouracil yelded high response rates,
but side-effects were often pronounced due to overlapping toxicity
(Andrè et al, 1999; Ajani et al, 2000; Roth et al, 2000). Roth et al
(2000) reported a 56% response rate with the docetaxel-cisplatin
combination. However, this schedule caused relevant haemato-
logic toxicity with a high number of grade III/IV episodes of
neutropenia (80% of the cycles) and non-fatal febrile neutropenia
in 19% of the patients. Ajani et al (2000) treated patients with
advanced gastric cancer with the combination of docetaxel,
cisplatin and fluorouracil. The incidence of grade III/IV
neutropenia was 72% per cycle. In addition, grade III/IV stomatitis
was observed in the 16% of cycles. Available data suggest that
about 20% to 30% of patients treated with these regimens do not
receive the treatment on schedule for dose reductions or delays,
and up to the 20% of patients discontinue therapy due to toxicity. 
Combining old anti-cancer drugs with new compounds is a
formidable challenge which requires several attempts to optimize
the efficacy/toxicity ratio. Sequential chemotherapy (Day, 1986)
and dose-dense schedules (Fizazi and Zelek, 2000) may offer this
opportunity. In the present experience, patients received first-line
chemotherapy with four of the most active drug in advanced
gastric cancer, and the toxicity profile of the PELF-docetaxel
chemotherapy seemed more favourable than that of new combina-
tions using a concomitant administration of drugs. Interestingly,
sequential docetaxel caused more episodes of grade II neutropenia
(35% vs 12% of cycles) and grade III thrombocytopenia (19% vs
10% of cycles) than the PELF induction. Also, fatigue was more
frequent after chemotherapy with docetaxel. According to our
protocol, filgrastim was used after every cycle of the PELF
regimen, whilst it was employed in the case of grade III–IV
neutropenia during docetaxel chemotherapy. This may explain
differences in the number of cycles with neutropenia between the
PELF regimen and docetaxel chemotherapy. Also, it is possible
that patients receiving the sequential programme were more likely
to experience side-effects due to the prolonged exposure to
chemotherapy with cumulative toxicity. 
In the first phase II study (Cascinu et al, 1997), the PELF
regimen showed 62% overall response rate which dropped to 46%
in a subsequent analysis in patients with locally advanced disease
(Cascinu et al 1998). In the present study, PELF chemotherapy
alone achieved 40% response rate which approached 60% after
docetaxel. The well-known ECF regimen showed 71% response
rate in early phase II studies (Findlay et al, 1994) which dropped to
45% in a randomized trial (Webb et al, 1997). Phase III trials
allows a proper analysis of response rates, survival, adverse events
and quality of life and they are necessary for the testing of second-
generation chemotherapy regimens in advanced gastric cancer.
The non-randomized design of the PELF trials does not allow any
definitive conclusion and any direct comparison for efficacy. The
high response rate showed by the PELF chemotherapy in the early
investigation needs to the confirmed in a randomized study, and 
a comparison with the PELF-docetaxel sequence would be of
interest. At present, we may consider the PELF-docetaxel as an
interesting evolution of the PELF regimen; this new sequential
combination showed a favourable toxicity/efficacy ratio and it
deserves further investigation in the palliative or neoadjuvant
setting. 
New combination chemotherapy regimens with substantial
response rates and moderate toxicity may be studied as neoadju-
vant chemotherapy (Kelsen, 1996). After PELF chemotherapy, 13
out of 32 patients with unresectable, locally advanced disease
underwent surgery and their tumour was completely removed
(Cascinu et al, 1998). Toxicity was acceptable, neither treatment-
related deaths, nor surgical complications were observed. Also the
ECF regimen was employed in the neoadjuvant setting (Findlay 
et al, 1994; Melcher et al, 1996). In these experiences, the ECF
chemotherapy showed mild toxicity, and it allowed surgery in
about half of patients with locally advanced disease. 
An innovative strategy of neoadjuvant chemotherapy should
consider the identification of patients with chemosensitive disease
(Reichle et al, 2000). In fact, sequential chemotherapy may display
the population of patients who may ulteriorly respond to non-cross
resistant agents. In our previous experience with the PELF
regimen (Cascinu et al, 1997), all patients but one achieved a
maximum response after 8 cycles and 6 more cycles of the same
chemotherapy did not improve the outcome. In the present study,
docetaxel following PELF induction gained major responses,
moreover, patients who improved after docetaxel had a major
tumor shrinkage rather than a simple turn of minor response to
partial response. This effect may be beneficial in a population of
patients with locally advanced disease, by increasing the chance of
successful surgical resection. 
In conclusion, the discovery of new active compounds and their
testing in multi-drug regimens has allowed progresses in the
medical management of gastric cancer. Future trials will confirm
or not the superiority of second-generation polychemotherapy
regimens and their role in the palliative or the neoadjuvant setting.
In this perspective, the PELF-docetaxel chemotherapy is worth of
further investigations and we are planning a phase II analysis in
neoadjuvant chemotherapy and a randomized trial of PELF vs
PELF-docetaxel in metastatic disease. 
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